Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix(TM) Biliary Stents

Latest Innovation in Plastic Biliary Stent Technology Includes Features for Enhanced Deliverability, Efficiency and Procedural Control

NATICK, Massachusetts, October 21, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced that it has
received 510(k) clearance from the U.S. Food and Drug Administration and CE
Mark approval to market its Advanix(TM) Biliary Plastic Stents for the
treatment of biliary strictures, including biliary stone disease, benign
biliary strictures, and suspected and confirmed malignancies in the biliary
system. The product is now available in Europe and other international
markets; the Company plans to launch it in the U.S. this quarter.

Endoscopic therapy, specifically with stent placement, has
gained acceptance as a first line of treatment for biliary strictures and
offers a less-invasive alternative to surgery. Results from a published study
of patients with post-operative benign bile duct strictures demonstrated that
stenting has similar long-term success rates and lower early complication
rates compared to surgery[1].

The Advanix Biliary Stent is designed to accommodate a range
of clinical requirements and includes features for improved deliverability in
navigating tortuous anatomy. It employs the NaviFlex(TM) RX Delivery System,
which offers physicians the flexibility to employ both long-wire and
short-wire guidewires during access and stent placement. The pre-loaded stent
within the delivery system enables physicians to reposition the stent,
helping to ensure accurate placement. The highly visible guidewire exit port
allows for easier manipulation during the procedure.

"The Advanix Biliary Stent System features significant
developments in plastic stent technology," said Stuart Sherman, M.D.,
Clinical Director of Gastroenterology and Hepatology, and Director of the
ERCP[2] program at Indiana University Medical Center in Indianapolis.
"Improvements in design provide greater procedural control and efficiency
while navigating tight strictures in the bile ducts, facilitating stent
placement and removal. The thin wall and increased inner diameter of the
stent may provide extended patency of the duct, which could improve treatment
outcomes."

"Boston Scientific remains committed to delivering innovation
and leadership in endoscopic stent technology," said Michael Phalen, Senior
Vice President, and President of Boston Scientific's Endoscopy Division. "The
Advanix Biliary Stent System represents the latest advances in plastic stent
design, enabling physicians to more efficiently and effectively treat
blockages in the bile duct. In addition, it strengthens our broad stent
portfolio and provides another solution for the ERCP suite."

Benign strictures in the bile duct are typically caused by
prior surgical procedures, biliary stones or chronic pancreatitis, a disease
in which digestive enzymes begin to break down and attack the pancreas.
Chronic pancreatitis is extremely painful and in severe cases, can lead to
infection, shock and respiratory failure. The most common cause of malignant
biliary obstruction is pancreatic cancer, which is rarely diagnosed in the
early stages, and is the second most common cause of death among
gastrointestinal cancers. Other causes of malignant biliary obstructions
include bile duct, liver and gallbladder cancer.

The Advanix Biliary Stent and NaviFlex RX Delivery System are
available in a variety of sizes and shapes to accommodate both malignant and
benign biliary strictures, distinct patient anatomies and physician
preferences.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

About Boston Scientific Endoscopy

Boston Scientific Endoscopy develops innovative technology for
less invasive, more efficient gastrointestinal procedures.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials, product performance,
competitive offerings and market position. If our underlying assumptions turn
out to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    Contact:
    Geraldine Varoqui
    Director International Public Relation
    Tel: +49-2102-489-461
    Mob: +49-170-782-85-58
    varoquig@bsci.com

    ---------------------------------

    [1] Davids, P., M.D., et al, "Benign Biliary Strictures: Surgery or
        Endoscopy," Annals of Surgery, 1993; 217(3) 237-243.
    [2] Endoscopic Retrograde Cholangiopancreatography

Contact: Geraldine Varoqui, Director International Public Relation, Tel: +49-2102-489-461, Mob: +49-170-782-85-58, varoquig at bsci.com